Cargando…
Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA. Rapid progress in the preclinical and clinic...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978118/ https://www.ncbi.nlm.nih.gov/pubmed/36873375 http://dx.doi.org/10.3389/fbioe.2023.1138596 |